Renal Outcome in Patients With COVID-19
Study Details
Study Description
Brief Summary
Acute kidney injury (AKI) is reported to occur in 0.5-9% of severe acute respiratory distress coronavirus 2-positive patients and AKI has been identified as an independent risk factor for in-hospital mortality. The present study aims to investigate the incidence of renal outcome of in-hospital patients diagnosed with COVID-19.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
Beginning in December 2019, a novel coronavirus, designated as severe acute respiratory distress coronavirus 2 (SARS-CoV-2), has caused an international outbreak of respiratory illness termed coronavirus disease 2019 (COVID-19). Although the clinical manifestations of COVID-19 are dominated by respiratory symptoms, some patients show severe kidney abnormalities. Acute kidney injury (AKI) is reported to occur in 0.5-9% of SARS-CoV-2 positive patients and AKI has been identified as an independent risk factor for in-hospital mortality. The present study aims to investigate the incidence of of renal outcome of in-hospital patients diagnosed with COVID-19.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
ICU patients Patients with COVID-19 requiring ICU care |
|
Non-ICU patients In-hospital patients with COVID-19 not requiring ICU care |
Outcome Measures
Primary Outcome Measures
- GFR loss [6 months post-hospital admission]
Serial assessment of serum creatinine and cystatin C
- Cystatin C as indicator of mortality [30 days post-hospital admission]
All-cause mortality
- Cystatin C as indicator of respiratory illness [30 days post-hospital admission]
Ventilator-free days
- Cystatin C as indicator of disease severity [30 days post-hospital admission]
Rate of intensive care unit admission
Secondary Outcome Measures
- Renal function changes during hospital stay [from hospital admission til discharge up to 6 months]
Serial biomarker assessment
- Incidence of AKI [Within 7 days after admission]
As determined by KDIGO criteria
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients with COVID-19 diagnosed by World Health Organisation (WHO) criteria
Exclusion Criteria:
-
Patients aged less than 18 years
-
Patients with stage-5 chronic kidney disease
-
Patients receiving maintenance dialysis
-
Recipients of solid-organ transplantation
-
Patients with AKI requiring renal replacement therapy
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University Hospital Giessen and Marburg, Giessen | Giessen | Hessen | Germany | 35382 |
Sponsors and Collaborators
- University of Giessen
Investigators
- Study Director: Werner Seeger, MD, University Hospital Giessen and Marburg, Giessen
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AZ 58/20